RATIONALE-315 Data Support Perioperative Tislelizumab Plus Neoadjuvant Chemo in Resectable NSCLC
Neoadjuvant tislelizumab plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab demonstrated efficacy in resectable non–small cell lung cancer.
Federico Cappuzzo Hematology Department Phase 3 Rationale 315 Trial Esmo Virtual Plenary Neoadjuvant Tislelizumab Bgb A317
Source: onclive.com